Bambusa Therapeutics
BBTX on NasdaqBiological products (no diagnostic substances)
Dilution Known so far: 10.6M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM. Every source
Bambusa Therapeutics’ latest filing is a Form 4 from . Every Bambusa Therapeutics filing is below, newest first.
Insiders 3 insiders bought $58.6M of Bambusa Therapeutics stock on the open market in the last 90 days. Every trade
RA CAPITAL MANAGEMENT, L.P. (Director) bought 2,953,820 BBTX at $15.79, worth $46.6M
IPO registration
Priced and listed · S-1/A filed Oct 26, 2026
- Final prospectus, offering priced 424B4
- Registration declared effective EFFECT
- Shares registered for exchange listing 8-A12B
- Amended registration S-1/A
- Registration filed S-1
- Amended draft registration DRS/A
- Draft registration, filed confidentially DRSFirst filing
All filings
Latest: the 6 newest filings, key filings first. Each other tab counts its kind among the 28 most recent EDGAR filings.
Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.
S-8Bambusa TherapeuticsBBTXLIVEEDGAR
3 insiders bought $58.6M of Bambusa Therapeutics stock on the open market in the last 90 days. Every BBTX insider trade
Offerings and dilution 6
| Date | Form | What it is |
|---|---|---|
| Oct 30, 2026 | 424B4 | Prospectus |
| Oct 30, 2026 | S-8 | Employee stock plan registration |
| Oct 29, 2026 | EFFECT | Registration declared effective |
| Oct 29, 2026 | S-1MEF | S-1MEF |
| Oct 26, 2026 | S-1/A | Registration for a share sale (amended) Key exhibits: Underwriting or sales agreement (EX-1.1), Material contract (EX-10.2), Material contract (EX-10.3), Material contract (EX-10.4), Material contract (EX-10.5), Material contract (EX-10.8), Material contract (EX-10.9), Material contract (EX-10.10), Material contract (EX-10.11) |
| Oct 9, 2026 | S-1 | Registration for a share sale Key exhibits: Warrants or notes (EX-4.1), Material contract (EX-10.1), Material contract (EX-10.4), Material contract (EX-10.6), Material contract (EX-10.7), Material contract (EX-10.11), Material contract (EX-10.12), Material contract (EX-10.13) |
Insiders 14
| Date | Form | What it is |
|---|---|---|
| Nov 3, 2026 | Form 4 | RA CAPITAL MANAGEMENT, L.P. (Director) bought 2,953,820 BBTX at $15.79, worth $46.6M |
| Nov 2, 2026 | Form 4 | Salvia Investment GmbH (10% owner) bought 375,000 BBTX at $16.00, worth $6M |
| Nov 2, 2026 | Form 4 | Shanshan Xu (Director) converted 163,596 BBTX at $0.00001, worth $2 |
| Nov 2, 2026 | Form 4 | Shanshan Xu (Director) reported option or other derivative trades in BBTX |
| Nov 2, 2026 | Form 4 | Helmut Wolfgang Jeggle (Director) bought 375,000 BBTX at $16.00, worth $6M |
| Oct 29, 2026 | Form 3 | New insider |
| Oct 29, 2026 | Form 3 | New insider |
| Oct 29, 2026 | Form 3 | New insider |
6 older insiders filings on EDGAR.
Governance 1
| Date | Form | What it is |
|---|---|---|
| Nov 3, 2026 | 8-K | Amends its charter or bylaws and makes a Regulation FD disclosure |
Other 7
Possible new shares
Known so far: 10.6M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM.
- 10.6M new shares from the 424B4 of Oct 30, 2026
Not read yet: warrants, convertible notes, options and RSUs and an ATM program.
Listing compliance
No listing notices in the 8-K item 3.01 filings SEC Tracker has read.
Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices
Trading halts
No trading halts for BBTX since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.
Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts
Insiders
Show the 2 latest Form 4 trades
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.
| Traded | Insider | Trade | Value | Stake | Notes |
|---|---|---|---|---|---|
| Nov 2, 2026 | Salvia Investment 10% owner | Open-market buy 375,000 shares | $6M at $16.00 | +4% | Their first open-market buy here in SEC Tracker's records. 3 days after the company's S-8 filed Oct 30, 2026. |
| Nov 2, 2026 | Helmut Wolfgang Jeggle Director | Open-market buy 375,000 shares | $6M at $16.00 | +4% | Their first open-market buy here in SEC Tracker's records. 3 days after the company's S-8 filed Oct 30, 2026. |
Open-market buys and sales (Form 4 codes P and S); planned sales are marked under a Rule 10b5-1 plan. Values as stated in each Form 4. Not investment advice. Every Form 4 for BBTX · Insider trades across companies
Coming up
- Offering lock-up ends, about 180 days after the 424B4 of Oct 30 424B4, filed Oct 30
- Offering lock-up ends, about 181 days after the 424B4 of Oct 30 424B4, filed Oct 30
Dates and exhibits are as stated in each filing on EDGAR; a date no filing states is not shown. Not investment advice.
Bambusa Therapeutics shares and listing
From the company's own filings; each row names its source. Not investment advice.
- Listing compliance8-K item 3.01No noticesin the filings read
Insider activity
3 insiders bought $58.6M of Bambusa Therapeutics stock on the open market in the last 90 days.
Cluster buy: 3 insiders bought $58.6M in the last 14 days
- Director bought $40M
- 10% owner bought $6M
- Director bought $6M
Similar companies
Same SIC code (2836 Biological products (no diagnostic substances)) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX